Erdafitinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Erdafitinib |
| DrugBank ID | DB12147 |
| Brand Names (EU) | Balversa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.38% |
Approved Indication (EMA)
Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pulmonary hypertension | 99.38% | DL |
| 2 | kyphoscoliotic heart disease | 99.27% | DL |
| 3 | amenorrhea (disease) | 99.26% | DL |
| 4 | rheumatoid arthritis | 99.25% | DL |
| 5 | amyotrophic lateral sclerosis | 99.06% | DL |
| 6 | brachydactyly-syndactyly syndrome | 99.03% | DL |
| 7 | amyotrohpic lateral sclerosis type 22 | 98.91% | DL |
| 8 | amyotrophic lateral sclerosis, susceptibility to | 98.88% | DL |
| 9 | axial spondylometaphyseal dysplasia | 98.83% | DL |
| 10 | Mills syndrome | 98.78% | DL |
| 11 | multiple endocrine neoplasia | 98.75% | DL |
| 12 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 98.73% | DL |
| 13 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | 98.72% | DL |
| 14 | bilateral parasagittal parieto-occipital polymicrogyria | 98.64% | DL |
| 15 | lethal arthrogryposis-anterior horn cell disease syndrome | 98.58% | DL |
| 16 | lower motor neuron syndrome with late-adult onset | 98.47% | DL |
| 17 | monomelic amyotrophy | 98.39% | DL |
| 18 | hypoalphalipoproteinemia | 98.25% | DL |
| 19 | infectious bovine rhinotracheitis | 98.25% | DL |
| 20 | malignant catarrh | 98.25% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.